Form 4: Co-Diagnostics Director Ted Murphy Reports Acquisition of 48,334 Shares Through RSU Vesting
Insider Transaction Report
Co-Diagnostics, Inc. Director Ted Murphy reported the acquisition of 48,334 shares of common stock on May 23, 2025, resulting from the vesting of restricted stock units.
Summary
- Ted Murphy, a Director at Co-Diagnostics, Inc. (CODX), acquired 48,334 shares of common stock on May 23, 2025.
- This acquisition resulted from the vesting of restricted stock units (RSUs) at a price of $0.00 per share.
- Following this transaction, Mr. Murphy directly beneficially owns 224,167 shares of Co-Diagnostics common stock.
- He also holds 103,333 unvested restricted stock units.
- The vested RSUs are part of multiple awards granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, with vesting schedules commencing from November 23, 2022, May 23, 2023, November 23, 2023, and November 23, 2024.
Sentiment
Score: 7
Explanation: The report indicates a routine vesting of restricted stock units for a director, leading to an increase in direct beneficial ownership. This is a positive sign of continued alignment between management and shareholder interests, though it's a scheduled event rather than a discretionary purchase.
Positives
- Director Ted Murphy increased his direct beneficial ownership of Co-Diagnostics common stock by 48,334 shares.
- The acquisition of shares through RSU vesting demonstrates continued alignment of management's interests with shareholders.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Director Ted Murphy received restricted stock units as part of the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, which are a form of equity compensation from the company.
Stakeholder Impact
- Shareholders: Increased direct ownership by a director through RSU vesting can be viewed positively as it aligns the director's financial interests with those of the shareholders.
Next Steps
- Future vesting installments of the remaining 103,333 restricted stock units held by Ted Murphy will occur according to their respective schedules (every six months from their commencement dates).
Key Dates
| Date | Description |
|---|---|
| 2022-07-07 | Award of 70,000 restricted stock units to Ted Murphy. |
| 2022-11-23 | Commencement of vesting for 70,000 restricted stock units awarded on July 7, 2022. |
| 2023-01-17 | Award of 40,000 restricted stock units to Ted Murphy. |
| 2023-05-23 | Commencement of vesting for 40,000 restricted stock units awarded on January 17, 2023. |
| 2023-06-12 | Award of 70,000 restricted stock units to Ted Murphy. |
| 2023-11-23 | Commencement of vesting for 70,000 restricted stock units awarded on June 12, 2023. |
| 2024-04-26 | Award of 110,000 restricted stock units to Ted Murphy. |
| 2024-11-23 | Commencement of vesting for 110,000 restricted stock units awarded on April 26, 2024. |
| 2025-05-23 | Transaction date for the vesting of 48,334 restricted stock units and acquisition of common stock. |
| 2025-05-27 | Signature date of the Form 4 filing. |
Keywords
Co-Diagnostics, CODX, Ted Murphy, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSU Vesting, Beneficial Ownership, Director, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.